Cellectar Biosciences, Inc.(CLRB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CLRB Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Cellectar Biosciences, Inc. (CLRB), a Healthcare sector company. CLRB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Cellectar Biosciences, Inc. reports net income of $-6.9M, free cash flow of $-6.0M. Top institutional holders of CLRB by reported 13-F value include Caligan Partners, StemPoint Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CLRB trades on the Nasdaq exchange and files with the SEC under CIK 1279704. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLRB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellectar Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-6.9M
Free Cash Flow
Q2 2026
$-6.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+51.1% YoYOperating Income
+55.6% YoYEPS (Diluted)
+80.1% YoYTotal Assets
-41.2% YoYOp. Cash Flow
+51.4% YoYFree Cash Flow
+51.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-21.8M +51.1% | $-44.6M -4.2% | $-42.8M -34.5% | $-31.8M -31.8% | $-24.1M -59.8% | $-15.1M |
| Operating Income | $-23.0M +55.6% | $-51.8M -32.9% | $-39.0M -35.2% | $-28.8M -19.4% | $-24.1M -57.8% | $-15.3M |
| EPS (Diluted) | $-4.17 +80.1% | $-20.95 -1096.9% | $-1.75 -55.2% | $-1.13 -937.3% | $-0.11 -136.3% | $-0.05 |
| Total Assets | $15.0M -41.2% | $25.5M +111.0% | $12.1M -44.1% | $21.6M -42.0% | $37.2M -36.6% | $58.7M |
| Operating Cash Flow | $-23.1M +51.4% | $-47.6M -47.0% | $-32.4M -28.4% | $-25.2M -11.8% | $-22.6M -62.0% | $-13.9M |
| Free Cash Flow | $-23.1M +51.5% | $-47.7M -43.5% | $-33.2M -30.6% | $-25.4M -12.1% | $-22.7M -62.3% | $-14.0M |
Get alerted when CLRB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cellectar Biosciences, Inc. including:
Top Institutional Holders of CLRB
Caligan Partners LP
$1.3M469,998 shStemPoint Capital LP
$986.7K354,938 shVANGUARD CAPITAL MANAGEMENT LLC
$910.1K327,367 shSILVERARC CAPITAL MANAGEMENT, LLC
$894.4K321,728 shBleichroeder LP
$802.5K288,679 shJupiter Topco LLC
$759.4K274,156 shBALYASNY ASSET MANAGEMENT L.P.
$611.6K220,000 shNantahala Capital Management, LLC
$611.6K219,998 shEmpery Asset Management, LP
$527.1K189,605 shDIADEMA PARTNERS LP
$384.6K138,341 sh
| Fund | Value | Shares |
|---|---|---|
| Caligan Partners LP | $1.3M | 469,998 |
| StemPoint Capital LP | $986.7K | 354,938 |
| VANGUARD CAPITAL MANAGEMENT LLC | $910.1K | 327,367 |
| SILVERARC CAPITAL MANAGEMENT, LLC | $894.4K | 321,728 |
| Bleichroeder LP | $802.5K | 288,679 |
| Jupiter Topco LLC | $759.4K | 274,156 |
| BALYASNY ASSET MANAGEMENT L.P. | $611.6K | 220,000 |
| Nantahala Capital Management, LLC | $611.6K | 219,998 |
| Empery Asset Management, LP | $527.1K | 189,605 |
| DIADEMA PARTNERS LP | $384.6K | 138,341 |
More Healthcare Companies
View all Healthcare →Put CLRB on your watchlist
Track score changes the day Cellectar Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CLRB a good stock to buy?
13F Pro's AI-powered analysis of Cellectar Biosciences, Inc. (CLRB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLRB are available on the CLRB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLRB is classified as a small company.
Which hedge funds own CLRB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLRB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cellectar Biosciences, Inc.'s investment landscape.